Analysts at StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS – Get Free Report) in a report issued on Saturday. The brokerage set a “sell” rating on the stock.
Separately, HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Senseonics in a research report on Wednesday, August 14th.
Check Out Our Latest Stock Report on SENS
Senseonics Trading Down 2.0 %
Senseonics (NYSE:SENS – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) EPS for the quarter, meeting analysts’ consensus estimates of ($0.03). Senseonics had a negative net margin of 335.15% and a negative return on equity of 299.69%. The firm had revenue of $4.87 million during the quarter, compared to the consensus estimate of $4.86 million. Sell-side analysts anticipate that Senseonics will post -0.13 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Senseonics
Several institutional investors have recently bought and sold shares of SENS. Cubist Systematic Strategies LLC lifted its stake in shares of Senseonics by 25.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after purchasing an additional 85,501 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Senseonics during the first quarter valued at about $162,000. Price T Rowe Associates Inc. MD lifted its position in shares of Senseonics by 16.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after buying an additional 51,000 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Senseonics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock valued at $11,963,000 after buying an additional 155,715 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System purchased a new position in shares of Senseonics in the 1st quarter worth approximately $91,000. 12.36% of the stock is owned by hedge funds and other institutional investors.
Senseonics Company Profile
Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.
Featured Articles
- Five stocks we like better than Senseonics
- What is Put Option Volume?
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Market Cap Calculator: How to Calculate Market Cap
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- What Are Some of the Best Large-Cap Stocks to Buy?
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.